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ABSTRACT

THE ROLE OF MATRIX METALLOPROTEINASES INDUCED ANGIOGENESIS
DURING TRANSITION FROM COMPENSATORY CARDIAC HYPERTROPHY
TO CARDIAC FAILURE: THERAPEUTIC EFFECTS OF HYDROGEN SULFIDE.

Dr.Srikanth Givvimani M.D
th

July 26 2010

Background: Although matrix metalloproteinase (MMPs) and tissue inhibitor of

metalloproteinase (TIMPs) playa vital role in tumor angiogenesis and TIMP-3
causes apoptosis, their role in cardiac angiogenesis is unknown. Interestingly, a
disruption of coordinated cardiac hypertrophy and angiogenesis contributes to
the transition to heart failure, however, the proteolytic and anti-angiogenic
mechanisms of transition from compensatory hypertrophy to decompensatory
heart failure are unclear. Previous studies have shown the cardio protective role
of hydrogen sulfide (H 2 S) in myocardial ischemia, infarction and heart failure, but
its role during transition from compensatory cardiac hypertrophy to heart failure is
yet to be unveiled. We hypothesize that in pathological pressure overload of the
heart, cardiac matrix remodeling is induced by an increase in angiogenic growth
factors during the compensatory hypertrophy phase and an increase in antiangiogenic factors during the decompensatory heart failure phase. H2S mitigates
vi

the transition from compensatory hypertrophy to decompensatory heart failure by
increasing angiogenesis and decreasing fibrosis.
Methods: In the first set of experiments, we have created ascending aortic

banding (AB) in the mice to mimic pressure overload on the heart and studied the
ventricular remodeling events associated with chronic pressure overload. Male
wild type mice were used and all animal procedures were performed in
accordance with National Institute of Health guidelines for animal research and
were reviewed and approved by the Institute Animal Care and use Committee of
University of Louisville. Sham animals underwent similar procedures except for
aortic banding. Animals were studied at 3 weeks (compensatory phase) and 8
weeks period (decompensatory phase) and compared with sham groups.
In the second set of experiment, similar protocol was followed, and
animals were treated with hydrogen sulfide (H2S) for 6 weeks by giving sodium
hydrosulfide (NaHS) in drinking water and compared with untreated groups.
Molecular and functional data were assessed by echocardiography, pressurevolume (P-V) study, immunohistochemistry, histology, western blot, and x-ray
angiography.
Results: We found that in the first set of experiments, expression of MMP-2

increased along with angiogenic growth factor, vascular endothelial growth factor
(VEGF) during compensatory phase (AB 3 weeks group). Expression of MMP-9,
TIMP-3 and anti-angiogenic factors, angiostatin, and endostatin increased during
decompensatory phase (AB 8 weeks group). There was increased deposition of

vii

fibrosis during the decompensatory phase. Sy treating with H2S, we noticed that
there was increased expression of VEGF and MMP-2 in AS 8 weeks group than
in untreated AS 8 weeks group. Interestingly, the expression of MMP-9, TIMP-3
and anti-angiogenic factors angiostatin and endostatin decreased in H2S treated
AS 8 weeks group than in the untreated group. There was significant reduction of
fibrosis in treated AS 8 weeks group. Left ventricular function also improved in
H2S treated AS 8 weeks group.
Conclusion: we conclude that under chronic pressure overload, expression of

MMP-2 is induced which in turn increases the release of angiogenic growth
factors in compensatory cardiac hypertrophy. The expression of MMP-9 and
TIMP-3 is also increased leading to a release of anti-angiogenic factors in
decompensatory heart failure. Hydrogen sulfide mitigates this transition to
decompensatory heart failure not only by inducing MMP-2NEGF but also
inhibiting MMP-9/TIMP-3 and anti-angiogenic factors.
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CHAPTER I
INTRODUCTION

Worldwide, cardiovascular disease (CVD) is the leading cause of mortality for
both men and women (Figures 1 and 2) (1). It includes hypertension, ischemia,
infarction, heart failure and stroke. Hypertension is one of the major risk factors
of heart failure. Nevertheless, it is unclear, why every hypertensive does not
develop heart failure. To develop treatment of CVD, it is important to determine
the mechanism(s) of heart failure. In 1941 Roberts et al. report that there is a
decreased ratio of capillary density to number of myofibers in hypertrophied
hearts, stressing the importance of angiogenesis in the pathogenesis of heart
failure. Since then wide range of research is ongoing to unravel the pathogenic
mechanism of heart failure.
Chronic heart failure (CHF) could be due to pressure overload and/or
volume overload. Systemic hypertension is the main risk factor of pressure
overload heart failure. Previous studies have shown that during chronic stress,
the heart undergoes remodeling resulting in compensatory hypertrophy initially,
and progressing to decompensatory heart failure in later stage. Remodeling by
its very nature implies synthesis and degradation of extracellular matrix (ECM).
The matrix metalloproteinase (MMP) and their natural tissue inhibitors (TIMPS),
1

play a major role in ECM remodeling and the pathogenesis of heart failure.
Proper angiogenesis/vasculogenesis is important to supply nutrients to the
remodeling tissue. It has been shown that disruption in the angiogenic process
leads to decompensatory heart failure, however, the exact mechanism of
transition from compensatory hypertrophy to decompensatory heart failure has
not been elucidated. Although angiogenic and anti-angiogenic factors have been
extensively studied, and a critical role of MMPfTlMP axis in cancer has been
demonstrated, their role in cardiac pathology has not been studied. In contrast to
cancer, angiogenesis or inhibition of anti-angiogenic factors may playa beneficial
role in ischemic cardiovascular diseases including heart failure, and therefore
pro-angiogenic therapy is a promising strategy for the treatment of cardiovascular
disease.
Hydrogen sulfide has recently been found to be an endogenous gaseous
transmitter similar to nitric oxide (NO) and carbon monoxide (CO). Several
mechanisms have been proposed to show the cardio protective vasodilatory and
pro-angiogenic mechanisms of hydrogen sulfide. Nevertheless, it is not known
whether hydrogen sulfide can have a therapeutic role in hypertension-induced
heart failure. In the present study, we examined the mechanisms involved in the
transition from compensatory to decompensatory heart failure,
therapeutic effects of hydrogen sulfide during this transition.

2

and the

1200
1000
Ib
'0

c:

co
tJ)

800

::::J

0

.c

....
c:

600

II)

.c
..,
co

400

CD

c

200
0

00

10

20

30

40

50

60

70

80

90

00

06

Years

Figure 1: Deaths due to cardio vascular disease in United States from 19002006 (AHA statistical update). The plateau during 1980 could be due to
awareness of healthy nutrition and advances in the medical management.
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CHAPTER II
BACKGROUND

a) Structure and function of the heart

The heart is a four chambered pumping organ (upper right and left atria
and lower right and left ventricles) in which the left side of the heart receives
oxygenated blood through pulmonary veins from the lungs and pumps it to the
rest of the body through the aorta. The right side of the heart receives
deoxygenated through the superior and inferior venacava, and pumps it to the
lungs via the pulmonary artery. The main function of the heart is to receive and
pump blood in a rhythmic manner (2). During contraction, the heart pumps blood
against the aortic pressure (afterload) which reflects vascular resistance. The
work load on the heart can be increased either by an increase in vascular
resistance (pressure overload) or by an increase in venous return (volume
overload). As the work load increases, the heart muscle has an intrinsic
compensatory mechanism to overcome the load and remodel accordingly.
Anatomically the heart can be differentiated into three layers: an inner
endocardial layer, middle myocardial layer and an outer epicardial layer. The
heart is surrounded by a pericardial sac and in the pericardial space there is
pericardial fluid that provides protection to the heart from external force or
5

friction.

The cellular structure of the heart consists of myocytes, fibroblasts,

smooth muscle cells, endothelial cells and extracellular matrix. Ventricular
myocytes contribute to 70 - 80% of the total cardiac mass (3) and the contractile
proteins of the heart lie within the myocytes. A group of myocytes held together
by collagenous connective tissue (a major component of extracellular matrix), is
called a myofiber. Approximately 50% of each ventricular cell is comprised of
myofibers and 25 - 33% consists of mitochondria (4). Vascular supply to the
heart is mainly by the right and left coronary arteries which arise from the aorta
just above the aortic valves. The left coronary artery divides into the left anterior
descending and the left circumflex arteries which supply most of the anterior
region, septum and posterior regions. The right coronary artery supplies the
lateral region of the right ventricle, right atrium and part of the posterior wall of
right ventricle (Figure 3). The specialized conduction system of the heart
originates in the sino atrial node (intrinsic pacemaker) in the high right atrium.
Impulses from the sino atrial node traverses through the atria to the atrio
ventricular node and then through the common bundle of His, which divides in
the ventricular septum as right and left bundle branches and terminates in
Purkinje fibers (Figure 4).
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Figure 3: Blood supply of the heart. Left coronary artery divides into left
anterior descending and left circumflex arteries which supply most of the anterior
region , septum and posterior regions. Right coronary artery supplies lateral
region of the right ventricle, right atrium and some part of the posterior wall of
right ventricle.
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b) Pathological conditions of the heart
Hypertension

High blood pressure / hypertension is a major risk factor of cardiovascular
diseases. According to the guidelines of the American heart association (AHA),
hypertension is defined as a systolic blood pressure (SBP) of
diastolic blood pressure (DBP) of

~

~

140 mm Hg or a

90 mm Hg. One in three adults in United

States is hypertensive (1, 5) and it is estimated that direct and indirect health
care cost associated with treatment of hypertension is $73.4 billion per year (1).
Increase in blood pressure during hypertension leads to adverse events in the
brain, heart, and kidneys through two related mechanisms. The first is the effect
of increased pressure on the structure and function of the heart and arteries, and
the second is the acceleration of atherogenesis. The former is directly related to
the blood pressure, whereas the latter requires an interaction with other CVD risk
factors, most importantly cholesterol (6). Hypertension increases pressure
overload (afterload) on the heart and influences cardiac remodeling. At the onset
of hypertension, the heart rate increases to compensate for the increase in
overload. Over time myocytes increase in size to further compensate for the
increased afterload by increasing the force of contraction to maintain stroke
volume. As the overload is sustained long-term, myocardial remodeling
progresses to an increase in wall thickness and chamber size that leads to
contractile dysfunction and heart failure (7-8). The structural abnormalities in the
hypertensive heart are not only limited to myocyte hypertrophy but also include
9

medial hypertrophy of the intramyocardial coronary arteries as well as collagen
deposition leading to cardiac interstitial fibrosis (4).

10

Cardiac hypertrophy

Hypertrophy of the cardiac myocyte can be either physiological, during
growth and exercise or it can be pathological, due to a persistent increase in
mechanical overload (9). Pathological hypertrophy has been associated with
pressure overload, volume overload, and ischemic cardiomyopathy (4). Unlike
physiological cardiac hypertrophy, pathological hypertrophy results in the loss of
myocytes and their fibrotic replacement leading to cardiac dysfunction and
sudden cardiac death (10-11). Pressure overload produces a disproportionate
increase in systolic wall stress, and results in concentric ventricular hypertrophy.
At the

cellular level,

cardiomyocyte

cross-sectional

area

is

increased,

predominantly because of the parallel addition of new sarcomeres. Volume
overload can induce either systolic or diastolic wall stress and result in eccentric
ventricular hypertrophy. Eccentric hypertrophy results in an overall increase in
myocyte length without a substantial increase in myocyte cross-sectional area
and is caused by the addition of new sarcomeres in series (12-13).
Sustained pressure overload results in excessive collagen deposition, an
increase in myocyte size, and a decrease in capillary density leading to heart
failure (Figure 6) (14).

In 1941 Roberts et al. demonstrated a decrease in

capillary to myocyte diameter ratio in hypertrophied human hearts compared with
normal adult hearts

(Fig 5) (15). The coronary blood flow is normal during

diastole in the hypertrophied heart but the vasodilatory reserve becomes
impaired, when the myocyte mass surpasses the blood supply. This impairment
11

in the coronary reserve leads to subendocardial ischemia and in combination
with cardiac fibrosis impairs diastolic relaxation leading to diastolic heart failure.
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Normal

CHF

Figure 6: Relationship of capillary endothelial cell density to the cardiac myocyte

hypertrophy (14) . There is lower capillary density and excessive deposition of
ECM in congestive heart failure heart (CHF) than in normal heart. Arrows point
to the capillaries (white) , hypertrophied myocyte (yellow) , and fibrosis (black) .
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Heart failure
According to the American Heart Association (AHA), an estimated 5.7
million of Americans are suffering with heart failure and 670, 000 new cases are
diagnosed each year. The estimated direct and indirect cost of treating heart
failure in the United States in 2009 was $37.2 billion per year (1).
Heart failure is defined as a pathophysiological state in which an
abnormality of cardiac function decreases the ability of the heart to pump blood
at a rate commensurate with the requirements of the metabolizing tissues (4).
Heart failure can also be better defined as a complex clinical syndrome that can
result from any structural or functional cardiac disorder that impairs the ability of
the ventricle to fill with or eject blood (16).
Heart failure can be due to: a) loss of myocytes (e.g., myocardial
infarction) or disorientation of cells (e.g., hypertrophic), b) an increase in afterload
(e.g., hypertension) c) valvular abnormalities d) arrhythmias, e) pericardial
abnormalities, and f) congenital deformities of the heart (6).

A clinical study

performed in 1993, reported changes in wall stress, wall thickness and
ventricular volume (Figure 7) (17),

associated with the progression of

compensatory hypertrophy to decompensatory heart failure.
Cardiac structural adaptations and maladaptations during remodeling
Under chronic pressure overload, compensatory hypertrophy occurs with
addition of sarcomeres in parallel, leading to thickening of myocytes without a
change in length. Sustained overload leads to the addition of new sarcomeres in
15

series, resulting in the dilatation of the ventricles. Also excessive stretch of
myocytes can lead to myocyte death, resulting in the deposition of collagen
(fibrosis) in heart failure (6).
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Figure 7: Morphological and functional changes during progression of
heart failure: clinical study by Pouler HG et aI. , (1993) showing the
morphological and functional changes associated with progression of heart
failure. During the compensatory period, the wall thickness gradually increases
while the wall stress and ejection fraction remain constant, whereas during
decompensatory stage the wall thickness and ejection fraction decrease while
the wall stress increases.
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c) Extracellular matrix

Cardiac extracellular matrix (ECM) is the collagenous structural foundation
which entangles cardiac myocytes, vascular smooth muscle cells and endothelial
cells to form a network in the heart. In the myocardium, cellular structures are
connected to ECM through integrins which provide a physical connection
between the cell surface and surrounding proteins in the matrix (Figure 8) (1819). The main components of myocardial ECM are type I and type III collagen,
which provide the structural integrity of the heart. Abnormal turnover of collagen
results in interstitial and perivascular fibrosis, leading to stiffening of the ventricle
(20-21 ).
It has been identified that not only the poor contractile nature of myocytes
but also the disturbance in the ECM contributes to the pathogenesis of cardiac
failure (22-23). Chronic heart failure is characterized by an imbalance in ECM
turnover leading to an accumulation of collagen in the myocardium, loss of
myocytes, and disruption of collagen fibrils (23-25). Remodeling, by its very
nature, implies synthesis and degradation of ECM, leading to alterations in the
ECM composition and concentration, but it is the aberrant remodeling in the
myocardial ECM that results in heart failure. The integrity of the ECM is regulated
by matrix metalloproteinases (MMPs) and their tissue inhibitors called tissue
inhibitors of matrix metalloproteinases (TIMPs).

18

A) Normal

B) Compensatory Hypertrophy
(Pressure overload)

C) Decompensatory
heart failure

Figure 8: Representation of extracellular matrix remodeling in the pathogenesis
of heart failure. A) Normal myocytes with intact matrix 8) Hypertrophied
myocytes with disrupted matrix and C) Disordered myocytes with excessive
interstitial matrix.
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d) Matrix metalloproteinases

Matrix metalloproteinases (MMPs) were first discovered by Jerome Gross
and Charles Lapiere in 1962 who observed the enzymatic activity in tadpole tail
metamorphosis (26). MMPs are calcium and zinc dependent extracellular
endopeptidases which are synthesized as inactive pro enzymes that need to be
activated either by auto proteolysis or by another MMP or serine proteases (23).
To date nearly 30 MMPs have been identified and are mainly classified as
collagenases, gelatinases, stromelysins, and membrane type (Figure 9) (23, 2728). Collectively MMPs can process and degrade all components of extracellular
matrix (29-30).
Tyagi and colleagues have demonstrated that myocardial latent MMPs
can be activated by oxidative stress during heart failure (31) . MMPs associated
with myocardial remodeling are, a) Collagenases: MMP-1 and MMP-13, b)
stromelysins: MMP-3, c) gelatinases: MMP-2 and MMP-9 and d) membrane type
matrix metalloproteinase: MMP-14 (Table 1) (23, 32). Rodents lack MMP-1,
however, MMP-13 replaces its function and degrades collagen types I, II, and III
(33). MMP-14 cleaves fibronectin, gelatin, and laminin-1 (34). MMP-2 and -9,
degrade collagen types I, IV, V. MMP-2 also cleaves collagen type III fragments
(35-36). MMPs act not only on ECM proteins but also on various cytokines and
growth factors. MMPs also influence cell proliferation, migration, differentiation
during embryogenesis, angiogenesis, and apoptosis. They are also involved in
host defense as well as tissue remodeling (37-40). MMPs play a role in

20

regulation of angiogenesis by altering the balance between angiogenic and antiangiogenic factors (41-43) .

.

Brooks and colleagues report that an angiogenic stimulus induces
vascular remodeling and defines the role of MMP-2 and integrin (avr33) (44-45).
During hypertrophic remodeling and angiogenesis, MMP-2 is constitutively
expressed (41, 46). Alternatively, MMP-9 is expressed in heart failure and
induces the expression of anti-angiogenic factors, endostatin and angiostatin (41,
47-48).
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Figure 9: A Basic domain structure of Matrix metalloproteinase is shown with the
three most important domains: single peptide domain, pro peptide domain, and
gelatin binding domain. Hemopexin domain plays an important role in substrate
binding and interactions with TIMPs (49). B: Basic structural differences between
different MMP types.

22

Table 1: Major classification of matrix metalloproteinases (MMPs)
MMPs

Cellular source

Role in cardiac pathology

Collagenases
MMP-1,-13
Gelatinases
MMP-2

Fibroblasts, VSMCs, endothelial
cells

Left ventricular systolic
dysfunction

VSMCs, fibroblasts,
macrophages cardiomyocytes,
VSMCs, neutrophils, fibroblasts,
cardiomyocytes, macrophages

Pro angiogenic, improves
cardiac function
Anti-angiogenic, promotes
collagen deposition and
fibrosis, cardiac dysfunction

VSMCs,fibroblasts,cardiomyocyt
es and macrophages

MMP-7 increases connexin
processing and promotes
arrhythmia

VSMCs, fibroblasts and
cardiomyocytes

Adverse left ventricular
remodeling and dysfunction

MMP-9

Stromelysins
MMP-3,-7

Membrane
type MMPs
MT1- MMP

VSMCs-vascular smooth muscle cells.
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e) Tissue inhibitor of matrix metalloproteinases
TIMPs are natural endogenous inhibitors of MMPs found in most tissues
and body fluids that play an important role in extracellular matrix remodeling.
TIMPs are 21-34 kDa proteins possessing 12 conserved cysteine residues.
Cysteine residues form six disulfide bonds that fold the protein into two domains
(Figure 10). TIMPs inhibit proteolytic activity of MMPs by forming non covalent
1:1 stoechiometric complexes that are resistant to heat and proteolytic
degradation (50). In humans, four TIMPs have been described namely, TIMP-1, 2,-3, and -4. TIMP-1 ,-2, and -4 are present in soluble forms where as TIMP-3 is
tightly bound to the matrix. TIMPs have differential action on

matrix

metalloproteinases (MMPs) and pro MMPs (51).
TIMPs not only inhibit MMPs but also have the ability to form complexes
with proMMPs and regulate the MMP activation process (52-56). TIMPs have a
wide variety of actions such as promotion of cell growth, anti-apoptotic activity,
steroidegenic activity, anti-angiogenic activity and embryogenic activity. The antiangiogenic activity of TIMPs was first demonstrated in chick embryo yolk sac (51,
57). TIMP-3 exhibits strong anti-angiogenic activity that can be seen in all stages
of angiogenesis (58).

TIMPs in cardiac remodeling

TIMPs have cellular actions that are independent of MMP inhibition.
Studies report that the inhibitory actions of TIMP-1 to -3 on endothelial cell
migration and/or angiogenesis in response to VEGF stimulation, is independent
24

of MMP inhibition (59). TIMPs induce proliferation of cardiac fibroblasts, which
play an important role in cardiac remodeling. TIMP-3 shows differential action on
cardiac fibroblasts depending on the time and localization of its expression after
tissue injury. Table 2 summarizes the role of TIMPs during cardiac remodeling
(60).
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Membrane
binding domain

MMP binding
pocket

Figure 10: Tertiary structure of Tissue inhibitor of Matrix metalloproteinase
(TIMP). Cysteines are linked to form six disulfide bridges
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Table 2: Classification of tissue inhibitor of matrix metalloproteinases (TIMPs)
TIMPs

Cellular source

Role in cardiac pathology

TIMP-1

VSMC, EC, cardiomyocytes
fibroblasts and macrophages

TIMP-2

VSMC, EC, cardiomyocytes
fibroblasts and macrophages

Induces fibrosis, inhibits all
MMPs except MMP-2 and MT1MMP
Induces cell proliferation,
inhibits all MMPs except MMP9, activates pro MMP-2

TIMP-3

Cardiomyocytes, VSMC,
fibroblasts

Induced apoptosis, antiangiogenic. Inhibits MMP-1 ,-2,
-13

TIMP-4

VSMC,fibroblasts,
cardiomyocytes

Cardiac specific and induce
apoptosis in transformed cells.
Inhibits MMP-1 ,-3,-9.

VSMC-vascular smooth muscle cell; EC-endothelial cell; MT1-MMP- membrane
type matrix metalloproteinase.
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f) Angiogenesis
The sprouting of new capillaries from the existing blood vessels defines
angiogenesis (61-62). It occurs in hypoxic areas and in areas with high metabolic
demand and low perfusion. In hypoxic tissue, the initiation of angiogenesis arises
from the production of angiogenic factors which upon binding with the receptors
on the endothelial surface cause endothelial cell activation. Further proliferation
and migration of activated cells into the surrounding matrix along with the
degradation of ECM by MMPs allow formation of tubular outgrowths from the preexisting blood vessels. Finally, smooth muscle cells and pericytes stabilize these
newly formed tubular structures to form a complete vascular structure (Figure 12)
(63). As new capillaries sprout and increase in density, the distance between the
adjacent vessels decrease causing increased diffusion, restoring oxygen and
nutrient supply to the hypoxic tissue (62). The term "angiogenic switch" was
introduced for a better representation of the initiation of angiogenesis depending
on the availability of promoting factors and inhibiting factors (Figure 11) (64).
Under normal physiological conditions, the regulation of angiogenesis
occurs by a fine balance between growth promoting and inhibitory factors. An
imbalance in these factors can result in increased angiogenesis as seen in
cancer, or decreased angiogenesis as seen in myocardial ischemia or coronary
artery disease. Previous studies demonstrate that the therapeutic angiogenesis
using growth promoting factors can increase blood supply to the ischemic
myocardium (65-67). Studies in cardiac specific inducible protein kinase B (AKT-
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1) transgenic mice show decreased angiogenesis during pathological remodeling
and report that both heart size and cardiac function are angiogenesis dependent.
The study further reported that the disruption of coordinated cardiac hypertrophy
and angiogenesis plays a role in the pathogenesis of heart failure (68).
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Figure 12: Schematic representation of the mechanism of angiogenesis.
A) Angiogenic factors produced during hypoxia bind to the receptors on the
endothelial cells activating them. 8) Proliferation and migration of activated cells
to form tube like structures. C) Smooth muscle cells provide structural support to
these structures and thus stabilizing them into new functional blood vessel.
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g) Angiogenic growth factors

During hypoxia, transcription factors such as hypoxia-inducible factor
(HIF-1) promote the synthesis of angiogenic growth factors (Table 3). Among
these factors, vascular endothelial growth factor (VEGF) is a highly potent
stimulator of capillary formation in vivo and has direct mitogenic actions on
endothelial cells (62-63, 69-70).
VEGF was first described in 1983 as a vascular permeability factor, which
is secreted by tumor cells and induces vascular permeability (71). In 1989, cDNA
cloning established that both vascular permeability factor and VEGF were the
same molecule (70, 72). The up-regulation of VEGF mRNA during hypoxia
shows that its production is induced to recruit blood vessels in ischemic tissue
(73-74). VEGF binds to its receptors on the vascular endothelial cell surface.
Tyrosine kinase receptors, Flt-1 and Flk-1 known as VEGF receptor-1 (VEGFR1) and VEGF receptor-2 (VEGFR-2) respectively, have strong affinity for the
VEGF molecule (75-77).
In the literature five types of VEGF are described, of which, VEGF-A is the
key

regulator

of

angiogenesis,

VEGF-C

and

VEGF-D

regulate

Iymphangiogenesis (Figure 13) (74, 78-79). During myocardial ischemia,
administration of angiogenic growth factor VEGF into the perivascular or
intracoronary areas improves coronary collateral flow in animal models (80).

32

Table 3: Promoters and inhibitors of angiogenesis
Endogenous angiogenic growth factors

Endogenous inhibitors of angiogenesis

Vascular endothelial growth factor
(VEGF) Angiogenin
Angiopoietin-1
Fibroblast growth factors:
-acidic (aFGF)
-basic (bFGF)
Follistatin
Hepatocyte growth factor (HGF)
Interleukin-8 (IL-8)
Placental growth factor
Platelet-derived endothelial cell growth
factor (PD-ECGF)
Platelet-derived
growth
factor-BB
(PDGF-BB)
Pleiotrophin (PTN)
Progranulin
Proliferin
Transforming
growth
factor-alpha
(TGF-alpha)
Transforming growth factor-beta (TGFbeta)
Tumor necrosis factor-alpha (TNFalpha)

MATRIX DERIVED:
Endostatin
Arresten
Thrombospondin-1 and-2
Tumstatin
Canstatin
Fibulin
NON-MATRIX DERIVED:
Angiostatin
Parstatin
Anti thrombin-III
Interferons
Interleukins
Platelet factor 4
OTHERS:
Tissue inhibitor of MMPs (TIMP)
Prolactin fragments
Chondromodulin
Troponin-I
Vasostatin
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Binding domain

iI•••_II.___II_II___ Cell membrane
Tyrosine kinase

VEGFR-l VEGFR-2
F~- lIKDR
VASCULOGENESIS
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(1-4

LYMPHANGIOGENESIS

Figure 13: Downstream effects of vascular endothelial growth factors (VEGF)

following binding to their corresponding receptors (VEGFR).

34

h) Anti-angiogenic factors

Anti-angiogenic factors are naturally produced as endogenous proteins,
embedded in the matrix. Their release from the matrix regulate angiogenesis
under physiological conditions (81).

Endogenous angiogenic inhibitors are

released by the action of MMPs and serine proteinases on ECM and vascular
basement membrane (82). Although most of the angiogenic inhibitors are matrix
derived, some are also fragments of ECM metabolites, hormones, clotting factors
or proteins synthesized by the immune system (81, 83). While anti-angiogenic
factors are extensively studied in cancer research, their role in cardiovascular
disease is not well known (41, 48). Endostatin, arrestin, and tumstatin are some
of the angiogenic inhibitors derived from the ECM. Angiostatin, interferons and
antithrombin III are non-matrix derived anti-angiogenic factors (83). A list of
endogenous anti-angiogenic factors is presented in Table 3.
A recent study reports the relationship between angiostatin, endostatin
and coronary collateral formation in which myocardial tissue is harvested from
diabetic and nondiabetic coronary artery disease (CAD) patients (48). Results
from the study show that the expression of angiostatin and endostatin increases
in diabetic CAD patients compared with non-diabetic patients and negatively
correlates with coronary collateralization. This data suggest the necessity of new
approaches towards pro-angiogenic therapy or inhibition of anti-angiogenic
mechanism in heart failure patients.
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Endostatin

Endostatin, first isolated by O'Reilly in 1997, is a 20-22 kDa C-terminal
fragment of collagen type XVIII (Figure 14) (83-84). The direct actions of
endostatin include, inhibition of vascular endothelial cell proliferation and
migration, apoptosis, and cell cycle arrest at G1 stage of cell division (85-86).
Indirectly, endostatin inhibits angiogenesis by blocking MMP-2 activity and
preventing the binding of VEGF to its receptor (Figure 15). It also stabilizes cell to
cell and cell to matrix adhesions preventing degradation of ECM junctions (8789). Although endostatin is extensively studied in cancer, its role in the
pathogenesis of heart failure is not clear. In a study involving coronary heart
disease patients, serum levels of endostatin are elevated along with the
decreased coronary collateral formation (90). These results suggest that
endostatin might play an important role in decreasing angiogenesis during
decompensatory heart failure.
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Figure 14: Formation of endostatin fragments from collagen XVIII by metaldependent cleavage , elastase and protease cleavage by cathepsin-L.
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Angiostatin

Angiostatin is a proteolytic fragment of plasminogen, released by the
action of matrix metalloproteinases. It is a 38kDa endogenous polypeptide that
has inhibitory action on angiogenesis. It was first discovered by O'Reilly and
colleagues in 1994 (91) and its structure consists of four Kringle domains (K1-4)
(Figure 16) (92-93).

Angiostatin inhibits angiogenesis by blocking the

proliferation and migration of endothelial cells (Figure 17). The inhibitory action of
angiostatin occurs through several mechanisms- a) blocking the integrins and
angiomotin, preventing endothelial cell migration, b) binding to the a and

~

subunits of ATP synthase, reducing energy resources (93), c) blocking the
actions of VEGF and bFGF on the vascular endothelial cells, and d) inhibiting
the proliferation of vascular endothelial cells (VECs) by arresting mitosis at G2M
transition (93-95). Angiostatin also promotes apoptosis of VECs by increaSing the
tyrosine kinase activity of focal adhesion kinase (FAK) (96). Yamahara et aI.,
report elevated levels of angiostatin as well as MMP-9 activity, in the serum of
heart failure patients (97). Their results suggest that angiostatin plays a
pathological role in the progression of heart failure.
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(K1-4)

Angiostatin (K1-3)

Figure 16: Formation of angiostatin from plasminogen (98) . tPA- tissue
plasminogen

activator;

uPA-

urikinase

plasminogen

phosphoglycerate kinase ; K-Kringle domains of plasminogen .
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i) Hydrogen sulfide
Although hydrogen sulfide (H 2 S) was considered as a toxic gas with rotten
egg smell, it has been recently recognized as a novel endogenous gaseous
transmitter similar to nitric oxide (NO) and carbon monoxide (CO). H2 S exerts
various beneficial actions in the cardiovascular system (99-102). These three
gaseous

transmitters

effectively

dilate

blood

vessels

through

different

mechanisms (Figure 18). H2 S is an emerging gaseous transmitter of interest due
to its protective role in brain, kidney, gastro intestinal tract, and more importantly,
the cardiovascular system. H2 S is endogenously generated by pyridoxal-5'
phosphate dependent enzymes cystathione 13 synthase (CBS) and cystathione V
lyase (CSE) using L-cysteine as a substrate (103). CBS is highly expressed in
the brain whereas CSE is mostly found in the vasculature (104-105). A defect in
CSE/H 2 S pathway is associated with many cardiovascular diseases suggesting
its importance in physiological functions (106-111).
Under physiological concentration, H2 S exerts its cardioprotective effect by
opening ATP sensitive potassium channels (K

ATP

channels) in vascular smooth

muscle cells and as well as in the myocardium (107). The heart is considered to
be one of the major sources of endogenous hydrogen sulfide, based on mRNA
expression of CSE and amount of H2 S generated (108). CSE knockout mice are
profoundly hypertensive, indicating the vasodilatory role of H2 S (112). Besides
vasorelaxation, H2 S promotes vascular endothelial cell related angiogenesis both
invitro and in vivo. This action is based on opening of KATP channels that in turn
42

activate

mitogen

activated

protein

kinase

(MAPK)

pathway

and

AKT

phosphorylation (113).
The vasoprotective role of H2 S is demonstrated in spontaneously
hypertensive rats (SHR), by daily administration of sodium hydrosulfide (NaHS),
a H2 S donor, for 8 weeks (114). A significant reduction, in blood pressure,
hypertrophy of intramyocardial arterioles, and ventricular fibrosis is observed with
NaHS treatment (114). In addition, supplementation of H2 S shows cardio
protective effects in animal models of ischemia and myocardial infarction (115116). Based on these findings, we sought to examine the therapeutic effects of
H2S during the transition from compensatory cardiac hypertrophy to heart failure.
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Endothelial Cell

Smooth muscle cell relaxation
Figure 18: Mechanism of action of endogenous gaseous transmitters-nitric oxide
(NO) , hydrogen sulfide (H 2S) and carbon monoxide (CO). All three gases cause
vasorelaxation but by different mechanism of action. NO and CO act by
activation of soluble guanylyl cyclase (sGC) and H2 S acts by opening of
potassium ATP sensitive (KATP) channels. CBS-cystathionine

p synthase;

NOS-

nitric oxide synthase; CSE-cystathionine y lyase; HO-1/2/3-heme oxygenase1/2/3; GTP-guanosine triphosphate; cGMP-cyclic guanosine monophosphate.
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CHAPTER III
HYPOTHESIS
OVERALL HYPOTHESIS: Chronic pressure overload instigates compensatory

cardiac hypertrophy, matrix remodeling (fibrosis), and increase in angiogenic
growth factors. Persistent overload leads to an increase in anti-angiogenic
factors resulting in decompensatory heart failure. Treatment with H2S mitigates
the transition from compensatory hypertrophy to decompensatory heart failure by
increasing angiogenesis and decreasing fibrosis.
Specific aims:
Hypothesis 1: A chronic increase in pressure overload induces MMP-2, which in

turn, induces the release of angiogenic growth factors during the compensatory
hypertrophy phase, while MMP-9fTIMP-3 releases anti-angiogenic factors during
decompensatory heart failure phase.
Aim 1: To determine whether chronic pressure overload induces MMP-2, which

induces the release of angiogenic growth factors during compensatory cardiac
hypertrophy.
Aim

2:

To

determine

whether

MMP-9fTIMP-3

are

induced

during

decompensatory heart failure and these in turn, induce the release of anti45

- - - - - - - - - - - - - - - - - - - - - - -

angiogenic factors angiostatin and endostatin, during decompensatory heart
failure.
In chapter IV, experiments associated with Aims 1 and 2 are presented.
Hypothesis 2: Treatment with H2S, during chronic pressure overload induces

MMP-2 expression and inhibits MMP-9!TIMP-3 thereby, promoting angiogenesis
which mitigates the transition from compensatory cardiac hypertrophy to heart
failure.
Aim 3: To determine whether the H2S induces MMP-2 expression and promotes

the release of angiogenic growth factors, leading to angiogenesis.
Aim 4: To determine whether the H2S inhibits MMP-9!TIMP-3 expression and

blocks the release of anti-angiogenic factors, leading to a decrease in fibrosis.
In chapter V, experiments associated with Aims 3 and 4 are presented.
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MMP-9,TIMP-3 Endostatin,
Angiostatin

1

H2S

Decreased
Angiogenesis

Figure 19: Hypothetical representation of pressure overload heart failure and

intervention by hydrogen sulfide. MMP-matrix metalloproteinase, TIMP-tissue
inhibitor of matrixmetalloproteinase, VEGF-vascular endothelial growth factor,
H2S-hydrogen sulfide.
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ANIMAL GROUPS
CONTROL

H2S

SHAM

N=15

N=9

AS 3 weeks

N=12

N=8

AS 8 weeks

N=12

N=8

Table 4 : Experimental animal groups used for the study.
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CHAPTER IV
MECHANISM OF TRANSITION FROM CARDIAC HYPERTROPHY TO HEART
FAILURE

The primary causes of heart failure are myocardial infarction, ischemia,
and chronic pressure overload (i.e. systemic hypertension and valvular
diseases). To overcome the initial stress, the heart undergoes compensatory
hypertrophy and left ventricular remodeling (117). However, if the overload is
sustained it results in decompensation and end-stage heart failure (118). During
cardiac hypertrophy, there is an imbalance in the ratio of capillary bed to the
cardiomyocytes, resulting in hypoxia, which increases the hypoxia-inducible
factors (119). The hypoxia inducible factors stimulate the release of proangiogenic factors, such as vascular endothelial growth factor (VEGF) (120-121).
VEGF is a highly potent angiogenic factor that promotes endothelial cell
proliferation, migration, extracellular matrix (ECM) remodeling and capillary
formation (69, 122-125). These cellular events are essential processes of
angiogenesis. The increase in production of VEGF and simultaneous decrease in
anti-angiogenic factors, such as endostatin and angiostatin cause a net increase
in angiogenesis (126). VEGF, fibroblast growth factor (FGF) and anti-angiogenic
factors like angiostatin and endostatin, regulate the process of angiogenesis
through activation of matrix metalloproteinases (MMPs) (42-43).
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The transition from compensatory hypertrophy to decompensatory heart
failure is regulated by discoordination of angiogenesis and hypertrophy during
heart failure (68). Angiostatin and endostatin significantly inhibit tumor growth
and vascularity in mice models by down regulating VEGF expression at both
mRNA and protein levels (127).

Interestingly, systemic administration of

recombinant angiostatin and endostatin in tumor models demonstrates tumor
regression by inhibition of angiogenesis (127). In another study on wound
healing, endostatin suppresses ischemia induced neo-vascularization (128) and
mediates its anti-angiogenic actions by inhibiting the function of pro-angiogenic
molecules, such as VEGF receptor (89) and activation of MMPs (88).
Alterations in cardiac gene expression during the transition from stable
hypertrophy to heart failure elicit marked up-regulation of genes encoding ECM
proteins (129-130). MMP-2 is constitutively expressed, and releases growth
factors from the matrix during constitutive remodeling/hypertrophy/angiogenesis
(46). MMP-9 is induced during heart failure (47) and generates cOllagen-matrix
fragments; such as endostatin and angiostatin (48). TIMPs have various effects
other than inhibiting MMPs. TIMP-1 induces fibrosis (131). TIMP-2 induces cell
proliferation (132). TIMP-3 induces apoptosis (133). TIMP-4, a cardiac specific
TIMP, induces apoptosis in transformed cells, but has no effect on normal cells
(134).

Although the role of pro-angiogenic and anti-angiogenic factors in the

process of neo-vascularization is well-known; the differential role of these factors
during the transition from compensatory cardiac hypertrophy to decompensatory
heart failure remains obscure. The present work examines the role and
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interaction of pro and anti-angiogenic factors during transition from compensatory
hypertrophy to heart failure. We hypothesize that a chronic increase in pressure
overload induces MMP-2, which in turn, induces the release of angiogenic growth
factors during the compensatory hypertrophy phase while MMP-9fTIMP-3
release anti-angiogenic factors during the decompensatory heart failure phase.
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MATERIAL AND METHODS:
Animals

Wild type (WT, C57BL6/J) and MMP-9-/- (MMP-9KO) mice were obtained
from Jackson Laboratories (Bar Harbor, Maine), housed in the animal care facility
with access to water and standard chow. All animals were 12 weeks old and
between 26-30 grams. All animal procedures were performed in accordance with
National Institute of Health guidelines for animal research and were reviewed and
approved by the Institute Animal Care and use Committee of University of
Louisville.
Pressure overload animal model

Under pentobarbital anesthesia, (70mg/kg body weight dose, through
intraperitoneal route) animals were intubated and ventilated. A left parasternal
thoracotomy was performed and the ascending aorta is identified and dissected.
Banding of the ascending aorta was done by placing a 26 g needle on the
anterior surface of aorta and a 6-0 silk suture was then ligated around the aorta
and the needle, and needle quickly removed resulting in constriction of aorta to
create pressure overload on the heart (130). The thoracotomy was then closed in
layers using 6-0 vicryl and 5-0 silk sutures for skin. Postoperative analgesia was
given through intraperitoneal injection of keoprofen at the dose of 5mg/kg body
weight for 48 hours. Sham animals underwent similar procedure except banding
of aorta. To perform a longitudinal study, starting at time zero, all experimental
results were compared with sham-operated mice at the same time post-surgery.
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We compared mice at 3 and 8 weeks post-operation to their corresponding sham
controls (n=5 per group).
Left ventricular weight and body weight ratio (LV WtlBW)

Animals were euthanized according to the IACUC protocol, and the
hearts were excised, rinsed in phosphate buffer saline (PBS), and right and left
ventricles were divided. Ratio of left ventricular weight and body weight was
measured and represented in bar diagram (Figure 25).
Antibodies and Reagents

The following primary antibodies were used for protein analysis: rabbit
polyclonal anti-angiostatin, mouse monoclonal anti-endostatin, rabbit polyclonal
MMP-2, and rabbit polyclonal MMP-9. These antibodies were purchased from
abcam (Cambridge, MA). Rabbit polyclonal antibody against VEGF (A-20), rabbit
polyclonal antibody against TIMP-2, -3, and TIMP-4, and HRP-conjugated
secondary antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Mouse monoclonal anti-GAPDH and all analytical reagents were from SigmaAldrich (St. Louis, MO).
Western blot analysis

Heart tissue from mice was harvested and washed thoroughly in PBS and
snap-frozen in liquid nitrogen. Protein extraction was done using 1X RIPA buffer
(Tris-HCI 50 mM,pH7.4; NP-40 1%; Na-deoxycholate 0.25%; NaCI 150 mM;
EDTA 1 mM; PMSF 1 mM; Na3V04 1 mM; NaF 1 mM; protease inhibitor cocktail
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1 Jig/ml). Estimation of protein was done by Bradford method (Bio-Rad, Hercules,
CA). 10-25 Jig of protein was fractionated by SOS-PAGE and transferred onto
PVOF membrane (BioRad, Hercules, CA) by wet transfer method. The
transferred proteins were processed for immunodetection of specific antigens.
Briefly, non-specific sites were blocked with 5% non-fat dry milk in TBS-T (50 mM
Tris-HCI, 150 mM NaCI, 0.1 % Tween- 20, pH 7.4) for 1 hour at room
temperature. The blot was then incubated with appropriate primary antibody in
blocking solution according to the supplier's specific instructions. The blots were
washed with TBS-T (three times, 10 minutes each) and incubated with
appropriate HRP-conjugated secondary antibody for 1 hour at room temperature.
After washing, ECl Plus substrate (Amersham Biosciences, Pittsburgh, PA) was
applied to the blot for 1 minute. The blot was developed using X-ray film (RPI
Corp, Inc., Mount Prospect, Il) with a Kodak 2000A developer (Eastman Kodak,
Rochester, NY). The blots were stripped and re-probed with GAPOH. The
immuno-reactive bands were scanned and densitometrically analyzed by UnScan-It software (Silk Scientific, Orem, UT).
Echocardiography

Two dimensional trans-thoracic echocardiography images of left ventricle
from

a four chambered

apical

view were taken with

a phased-array

echocardiography machine (SONOS 1500 or 2500; Hewlett-Packard, Inc.) using
a 12.5-MHz transducer in anesthetized mice at baseline, 3 and 8 week post
operation. Animals were given intraperitoneal injection of Tri-bromo ethanol
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anesthesia (TBE) (135) at a dose of 240 mg per kilogram body weight, depilated
and placed on a self regulating heating pad to maintain normal body
temperature. Cardiac function, left ventricular internal dimension in diastole
(LVIDd), left ventricular internal dimension in systole (LVIDs), left ventricular
posterior wall dimension (LVPWD), and %Ieft ventricular fractional shortening
(%FS) were assessed.
Histological analysis of cardiac sections

Frozen sections were cut at 8

~m

thickness using cryocut 1800 (Reichert-

Jung). Cryosections were placed on superfrost plus microscope slides and air
dried. Histological analysis was done in all three groups using Masson's
trichrome blue staining for detection of fibrosis, hematoxylin and eosin (H and E)
staining for overall morphology.
Immunohistochemistry

Immunohistochemistry was performed on 5

~m

thick frozen sections of

the heart using standard Immunohistochemistry (IHC) protocol. Anti-Endostatin
(Abcam) and anti-TIMP-2, secondarily conjugated with Texas Red (Chemicon
International, St. Charles, MO) were used for immunodetection of these two
proteins, respectively. Anti-platelet endothelial cell adhesion molecule (PECAM)
(also called CD31) clone-390, secondarily conjugated with FITC (Chemicon
international, St.Charles, Missouri) was used to detect collateral density of microvessels.
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Coronary Angiograms

Barium sulfate contrast coronary angiograms were done on excised
hearts to visualize the differences in vascular density between all three groups of
mice and MMP-9 Ko AB 8 weeks mice. Barium sulphate was mixed in 5.5 pH
buffer and perfused via carotid artery into the heart at a constant flow rate using
syringe pump (Chemyx Inc,Stafford,TX) and x-ray angiograms were taken with
KODAK MM4000 mm imaging system (Carestream Health Inc, Rochester,NY).
Pressure volume loop study (P-V loop)

Using

Millar

Pressure-Volume

system

(Millar

Houston,TX), following standard Millar protocol, steady state

Instruments

Inc,

P-V loops were

recorded followed by saline bolus and cuvette calibration for the conversion of
RVU (relative volume units ) to ilL.
analyzed

by

PVAN

software.

Hemodynamic variables obtained were

The

results

were

used

to

substantiate

echocardiography findings.
Statistical analysis

All data were expressed as mean ± SE. Data were analyzed using a oneway analysis of variance (ANOVA) to test for treatment effects, and differences
between groups were determined using Tukey's post hoc test. A p value <0.05
was considered significant.
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Figure 20: Image showing an intubated mouse under ventilator support for the
aortic banding procedure.
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Figure 21: Photograph of mouse undergoing the aortic banding procedure. The
segment of ascending aorta to be ligated is shown by arrow.
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Figure 22: Image of barium contrast coronary angiogram in mouse using Kodak
4000 MM image station.
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RESULTS:
Echocardiography data showed an increase in septal and left ventricular

posterior wall thickness following 3 weeks of aortic banding (Figure 23).
Fractional shortening was significantly decreased after 8 weeks of aortic banding
compared with sham animals and/or mice 3 weeks post aortic banding. LVIDd
increased after 3 weeks aortic banding and LVPWd increased after 8 weeks of
aortic banding compared with sham controls. Interestingly, the left ventricular
chamber size was increased after 8 weeks of aortic banding, suggesting that the
heart had become dilated. The increase in ventricular wall thickness after 3
weeks aortic banding suggests LV hypertrophy (Figure 23). These data
demonstrate the transition from the compensatory phase observed at 3 weeks to
decompensatory heart failure after 8 weeks of aortic banding.

The P-V relationship data revealed that LV function was decreased after

8 weeks of aortic banding in comparison with sham controls. Quantitative data
obtained by P-V loop analysis, shows a decrease in ejection fraction and stroke
volume after 8 weeks aortic banding. Also end systolic volume was increased
after 8 weeks in comparison to sham controls (Figure 24).

Gravimetric data revealed increase in LV weight/body weight ratio at 3

weeks aortic banding and decrease at 8 weeks of aortic banding (Figure 25).
These data suggest compensatory hypertrophy at 3 weeks and decompensatory
heart failure at 8 weeks of aortic banding. To determine interstitial and
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pericapillary fibrosis, trichrome-blue collagen histological staining was performed.
Although basal level of collagen was detected in the sham group (Figure 26),
there was increased collagen deposition at 3 weeks post aortic banding. The
fibrosis was abundant at both the interstitial and epicardial regions of the hearts
from 8 weeks aortic banding mice.

MMPslTlMPs axis and angiogenic/anti-angiogenic factors in compensatory
to decompensatory heart failure

The expression of MMP-9 showed very little increase at 3 weeks aortic
banding compared with sham (Figure 27). However, the expression was robust
at 8 weeks post banding compared with either sham and/or 3 weeks banding.
Contrary to MMP-9, MMP2 was increased at 3 weeks. Interestingly, this increase
was almost normalized at 8 weeks post aortic banding (Figure 27). These results
suggested a differential role of MMP-2 versus MMP-9 during transition from
compensatory cardiac hypertrophy to decompensatory heart failure.
The expression of TIMP-2 is decreased at 3 and 8 weeks, compared with
sham control (Figure 28). However, a gradual decrease in TIMP-4 expression
was observed from 3 weeks to 8 weeks post aortic banding (Figure 28). This
suggested that TIMP-2 and TIMP-4 levels are decreased in decompensatory
heart failure.
Since TIMP-3 instigates apoptosis, we measured the levels of TIMP-3
along with MMP-2, in situ. Although MMP-2 and TIMP-3 co-localized, contrary to
TIMP-2ITIMP-4, the immunohistochemistry data revealed an increase in TIMP-3
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levels at 3 weeks, however, interestingly, at 8 weeks of aortic banding hearts the
decrease in TIMP-3 was robust (Figure 29). In situ data also revealed that MMP2 was elevated during 3 weeks with tendency to decrease at 8 weeks of aortic
banding compared with sham (Figure 29).
Since MMP-2 releases growth factors from the matrix and promotes
angiogenesis, we measured the levels of angiogenic VEGF and anti-angiogenic
(endostatin and angiostatin) levels. The levels of VEGF-A were increased in 3
weeks group compared with sham controls (Figure 30). However, the expression
of VEGF-A was diminished during 8 weeks post aortic banding, suggesting the
decrease in angiogenic factors in decompensatory heart failure (Figure 30). The
expression of anti-angiogenic factors like endostatin and angiostatin increased
significantly at 8 weeks post aortic banding when compared with sham and/or 3
weeks banding (Figure 30). The increase in expression of endostatin at 8 weeks
aortic banding was further evidenced by immunohistochemical staining (Figure
31 ).
Angiogenesis/vasculogenesis

The CD31 staining (an endothelial cell marker) showed increased density
of endothelial cells during 3 weeks compared with sham and 8 weeks aortic
banding groups, suggesting increased endothelial cell density (Figure 32).
Interestingly,

staining

with

CD31

also

visualized

the

capillary

density,

represented by endothelial cells density and was also increased at 3 weeks
compared with sham or 8 weeks aortic banding.
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To corroborate CO-31 endothelial/capillary data with vasculogenesis, we
performed in vivo real-time soft-tissue x-ray angiography using barium as
contrasting agent. The angiography data showed increased in vascular density at
3 weeks aortic banding; whereas capillary rarefaction was observed at 8 weeks
post aortic banding (Figure 33). To determine the role of MMP-9 as inducers of
anti-angiogenic factors (endostatin and angiostatin), we created aortic banding in
MMP-9-/- (MMP-9KO) mice. The results suggested increase in vascular density
in MMP-9KO after 8 weeks aortic banding compared with sham controls (Figure
33).
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Figure 23: Aortic banding induced changes in cardiac function

Panels represent M-mode echocardiography of sham (8 weeks) , 3 weeks
and 8 weeks after aortic banding. The bars graphs represented percentage of
fraction shortening (FS) , LVIDd (left ventricular internal dimension in diastole),
and LVPWd (left ventricular posterior wall dimension in diastole).
compared with sham. Data are mean ± SE; n = 5/group
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*p<O.05
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Figure 24: Changes in cardiac function due to aortic banding
Pressure-volume loop by Millar catheter of sham and 8 weeks aortic
banding mice: The bar graphs depict % ejection fraction (EF), ESV (End systolic
stroke volume) ,' and stroke volume (SV) in sham and 8 weeks aortic banding
mice. Data are mean ± SE; n=5/group *p<O.05 vs sham.
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Figure 25: Aortic banding increase cardiac mass.

A) The gross images of the whole heart of sham, 3 weeks, and 8 weeks
aortic banding. Hearts were cleaned in phosphate buffered saline. The left
ventricle was separated. B) The ratio of left ventricle (LV) weight (wt) to body
weight (BW) was depicted in bar graph. Data are mean ± SE; n=51 group.
*p<O.01 vs sham.
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Figure 26: Aortic banding induced changes in cardiac morphology
Representative microphotographs of Masson's-trichrome blue histological
staining of frozen heart sections: The hearts from sham, 3 weeks, 8 weeks and
MMP-9 KO 8 weeks aortic banding were analyzed. Arrow indicates endocardial
and peri-capillary fibrosis . 20 x magnifications. The insert box, 100 x
magnifications.

67

Sham 3wks
,------, i

55
eo:

8wks

--

I I

proMMP-9
active MMP-9
GAPDH

Sham

3wks

·ProMMP-9
• Active MMP-9

-=4
rI'J

~3
QI

~2

.!1
~
:90
~
0 4

8wks
II

proMMP-2
active MMP-2

**

....=

* ·ProMMP-2

rI'J

• Active

~ 3

MMP-2

~

Q.,

~ 2

GAPDH

....= 1
QI
.....

0

~

~

~

0

Sham

3wks

8wks

Figure 27: Western blot analyses of MMP-9 and MMP-2 expression in Sham , 3
weeks and 8 weeks of aortic banding: Bar graphs showed densitometric analysis
of MMP-9 and MMP-2 expression over sham groups (protein normalized with
GAPDH). Each bar represents mean ± SE , *p<O.05 vs sham , ** compared with 3
weeks , from n=5 in each group. The percent protein expression on Y-axis is the
protein expression calculated as fold change vs. sham.
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Figure 28: Western blot analyses of TIMP-2 and TIMP-4 expression in Sham, 3
weeks and 8 weeks of aortic banding: Bar graphs showed densitometric
analyses of TIMP-2 and TIMP-4 expression over sham groups (protein
normalized with GAPDH). Each bar represents mean ± SE, *p<O.05 vs sham, **
compared with 3 weeks, from n=5 in each group. The percent protein expression
on Y-axis is the protein expression calculated as fold change vs. sham.
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Figure 29: Left ventricle Immunohistochemical staining and co-localization of

TIMP-3 and MMP-2: Cryocut frozen sections of (8-10 J..lm) were stained and
secondarily conjugated with FITC for TIMP-3 and texas red for MMP-2 (white
arrows

indicate

capillaries).

The

bar

diagrams

depicted

the

intensity

quantification of TIMP-3 and MMP-2 by Fluoview software , in sham , 3 weeks and
8 weeks aortic banding . Data presented mean ± SE; *p<O.01 vs sham; **p<O.05
vs 3 weeks; n=5 animals per group.
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Figure 30: Measurement of angiogenic and anti-angiogenic factors: Western blot
analyses of VEGF-A, endostatin and angiostatin. Bar graphs showed the relative
expression of VEGF-A, endostatin , and angiostatin over sham group (after
normalization with GAPDH). The data presented mean ± SE, *p<O.05 vs sham;
**, compared with 3weeks. The percent protein expression on Y-axis is the
protein expression calculated as fold change vs. sham.
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Figure 31: Immunohistochemical staining of endostatin. Cryocut frozen tissue
sections (5 11m) are stained with anti-endostatin antibody secondarily conjugated
with Texas red dye. Nuclei are stained with DAPI. Bar diagrams depicted
intensity quantification by image pro-software. Each bar representative mean ±
SE , **p<O.05 vs sham or 3 weeks , n=5 animals/group.
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Figure 32: Immunohistochemical staining with CD31 (PECAM) in sham , 3 weeks
and 8 weeks aortic banding groups. DAPI was used for nuclear staining. The
images were merged . The arrows point to capillary structure. Bar diagrams
represent quantified arbitrary number of CD 31 staining endothelial cell in
capillaries per each field randomly selected with the help of Image-Pro software.
The data presented mean±SE, n=51 group. *p<O.01 vs Sham; **p<O.05 vs 3
weeks.
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Figure 33: Barium-contrast x-ray angiograms, to demonstrate gross variability in

vasculature among sham, 3 weeks, 8 weeks and MMP-9KO (at 8 weeks). In vivo
hearts were perfused with Barium sulfate solution and x-ray imaging was taken
with KODAK MM4000 both in whole body and in isolated hearts. The bar
diagrams depicted quantified intensity of the images from randomly chosen areas
of same size, with Image-J software. The data presented mean±SE, *p<O.05 vs
sham; **p<O.01 vs 3 weeks; ***, compared with 8weeks. n=5 animals per group.
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Figure 34: Hypothetical presentation of latent MMP activation under chronic
oxidative load condition. The imbalance in MMP/ TIMP axis and remodeling,
generating angiogenic, anti-angiogenic, factors, leading to apoptosis and chronic
heart failure (CHF). Abbreviations: ROS, reactive oxygen species; RNS, reactive
nitrogen species; RTS, reactive thiol species; NADH, nicotinamide adenine
dinucleotide (reduced); SOD, superoxide dismutase; Prx, peroxiredoxin; VEGF,
vascular endothelial growth factor; ADAM, a disintegrin and metalloproteinase;
Meprins, metalloproteinase in renal; iNOS, inducible nitric oxide synthase; eNOS,
endothelial nitric oxide synthase; GSSG/GSH, oxidized glutathione/reduced
glutathione; MT-MMP, membrane type-MMP.
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Discussion:

Systemic hypertension causing left ventricular pressure overload, is one of
the leading risk factors of cardiac hypertrophy that eventually leads to heart
failure. These hypertrophied hearts exhibit contractile dysfunction, dilation of the
ventricular wall and increased wall thickness (136). In the normal human heart,
after acute ischemic injury, LV wall stress increases, whereas wall thickness and
ejection fraction decreases. To compensate for the overload, the entire
myocardium undergoes compensatory hypertrophy/remodeling, Le; enlargement
of the muscle tissue and remodeling of the entire chamber. The ejection fraction
and wall thickness decreased significantly during decompensatory phase, though
it is maintained near normal level during compensatory phase (17). Our studies
suggest that there is an increase in MMP-2, decrease in TIMP-2 and -4, increase
in angiogenic factors and vascularization in compensatory hearts. However, in
decompensatory hearts there was an increase in MMP-9, TIMP-3, endostatin,
angiostatin, and vascular rarefaction. The increased expression of VEGF-A
during 3 weeks post aortic banding showed the importance of angiogenesis
during hypertrophy. There was an increase in the expression of angiostatin and
endostatin in the 8 weeks post aortic banding. These data suggest that higher
levels of angiogenic factors provide impulse for cardiac compensation while upregulation of anti-angiogenic factors promotes decompensatory heart failure.
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During angiogenesis, increased expression of VEGF was associated with
a simultaneous decrease in anti-angiogenic factors, such as endostatin and
angiostatin. Endostatin is derived from collagen XVIII, inhibits angiogenesis (84)
and induces endothelial cell apoptosis (85, 137). Angiostatin is a cleavage
product of plasminogen. Angiostatin is reported to induce endothelial cell death
(138-140), inhibits endothelial cell proliferation, (141) migration and tube
formation (142). Our study demonstrated that increased capillary density, as
evidenced by increased endothelial cell population, was observed during 3
weeks of aortic banding, and this was supported by the evidence of up- regulated
VEGF-A and basal level of endostatin and angiostatin expression. Conversely,
during decompensatory heart failure (8 weeks aortic banding), VEGF-A was
diminished and up regulation of endostatin and angiostatin was observed
resulting in a decrease in capillary density.
The endogenous inhibitors of MMPs, TIMPs, inhibit MMP activity;
therefore, the balance of MMPsfTlMPs is very important in order to maintain
normal physiological matrix architecture (143). MMP-2 and 9 both are able to
cleave collagen and play a major role in ECM remodeling. During cardiac
hypertrophy and chronic heart failure, the imbalance of MMPsfTlMPs caused
changes in matrix composition, resulting in cardiac fibrosis. TIMP-2 and TIMP-4
inhibit both MMP-2, and -9, and therefore, a decrease in TIMP-2 and TIMP-4
augments MMP-2 and -9 activities that promote cardiac fibrosis. The results of
this study show that increased fibrosis was observed at 8 weeks post aortic
banding. This is consistent with up regulation of MMP-9. Interestingly, an up
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regulation of MMP-2 was observed at 3 weeks and a down regulation of MMP-2
was observed in 8 weeks aortic banding. This suggests possible differential
regulation of these two MMPs by TIMP-2 and TIMP-4 during compensatory
cardiac hypertrophy leading to decompensatory heart failure. Moreover, TIMP-3
expression increased at 3 weeks and continued to increase at 8 weeks aortic
banding. This may suggest TIMP-3 associated cell death (133).
In conclusion,

our study showed that pressure overload cardiac

hypertrophy was compensated with increased angiogenesis and MMP-2,
whereas decompensatory heart failure was accompanied with an increase in
MMP-9 and TIMP-3, resulting in non-specific collagen cleavage and up
regulation of potent antiangiogenic factors that eventually led to heart failure
(Figure 34). The novelty of this study was the mechanistic disconnect between
angiogenesis/hypertrophy

in

compensatory

heart

to

anti-

angiogenesis/hypertrophy in decompensatory heart failure.
Limitations: Although we do not have a direct connection as to whether the

MMP-2 releases angiogenic factors and MMP-9/TIMP-3 releases anti-angiogenic
factors in stressed hearts, we show data that the levels of MMP-2 and -9, TIMP2, -3 and -4, VEGF, angiostatin and endostatin are modified in the direction
suggested by the hypothesis, which suggests a causal relationship. With
immuno-Iabeling, presumably, we detected both inactive pro and active MMP-2.
Also, the histochemical data shown in Figure 29 detected total active and pro
MMP-2. However, without a change in active MMP-2, we cannot infer specifically
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that MMP-2 elevation was responsible for the pro-angiogenic changes at 3
weeks. Because the blood flow in coronary arteries was pulsatile, we may be
unclear whether we really estimated the vascular density by measuring black
pixels. However, we have taken the images of the heart in diastole using KCI at
the same time of cardiac cycle. In MMP-9KO mice, the amelioration of cardiac
dysfunction in many cardiac disorders were already demonstrated (144-146),
here we showed that in the MMP-9 KO AB 8 weeks mice, there was absolute
decrease in fibrosis (Figure 26), and also there was an increase in vascular
density (Figure 33).
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CHAPTER V

ROLE OF HYDROGEN SULFIDE DURING TRANSITION FROM CARDIAC
HYPERTROPHY TO HEART FAILURE
Introduction: Cardiovascular disease (CVD) is the leading cause of death for

both men and women. Hypertension is the major risk factor of CVD (1). Although
initial pressure overload during hypertension is compensated by cardiac
hypertrophy, sustained overload results in progression towards heart failure due
to an imbalance in myocyte-capillary ratio (15, 147). In previous studies we
demonstrated that during the compensatory hypertrophy phase, MMP-2 is
induced and leads to the production of angiogenic growth factors like VEGF and
promotes angiogenesis. In later stages of compensatory hypertrophy, MMP-9
and TIMP-3 are induced and play a significant role in the production of antiangiogenic growth factors like endostatin and angiostatin. This leads to apoptosis
and

causes

transition

from

compensatory

cardiac

hypertrophy

to

decompensatory heart failure (41). Recent studies report that the endogenous
gaseous transmitter, hydrogen sulfide (H 2 S) plays an important role in cardiac
protection during ischemia, infarction and heart failure (108, 116, 148-149). H2 S
is endogenously generated by pyridoxal-5' phosphate dependent enzymes,
cystathione

~

synthase (CBS) and cystathione V lyase (CSE) using L-cysteine as

a substrate (103). CBS is highly expressed in the brain whereas CSE is mostly
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found in vasculature (104-105). H2 S promotes vascular relaxation and also has a
negative inotropic effect on cardiac muscle. Both effects are attributed to the
ability of H2 S to open potassium sensitive ATP channels (KATP), which are widely
distributed in coronary vasculature and myocardium (150). Studies quantify the
expression of CSE in the heart and correlate it with levels of H2 S. The results
suggest that the heart is one of the major sources of endogenous H2 S (108).
Mutant mice lacking CSE exhibit pronounced hypertension and diminished
endothelium dependent vasorelaxation (112). This provides evidence that H2 S is
a physiological vasodilator and regulator of blood pressure. Exogenous
supplementation of H2S decreases medial thickening of intracardiac coronary
vessels and reduced interstitial fibrosis in spontaneously hypertensive rats,
suggesting that H2 S increases the coronary reserve in hypertrophied hearts
(114). Hypertrophied hearts are protected against severe ischemia by promoting
angiogenesis (151). In vitro, VEGF causes an increase in H2S release in
endothelial cells while pharmacological inhibition of H2 S production or KATP
channels attenuates VEGF signaling and EC migration (113). The pro-angiogenic
effect of H2 S involves the signaling mechanism via AKT phosphorylation and
activation of the MAPK pathway (152).
MMPs and their natural endogenous inhibitors, TIMPs are predominantly
present in the heart

and their expression is upregulated under pathological

conditions (153). MMP-2 and MMP-9 are the two important gelatinases that play
an important role in the development and remodeling of the heart and
vasculature (154). Previous studies report that MMP-2 plays a significant role in
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angiogenesis and heart valve development (155-156). Knockout mice deficient in
MMP-2 have various anomalies of the heart during embryogenesis (42, 46, 157158). Brooks and colleagues report that an angiogenic stimulus induces vascular
remodeling through activation of MMP-2 and integrin

(av~3)

(44-45). Although

previous studies report that the MMP-2 expression and activity were significantly
elevated in VEGF treated hypertrophied hearts (42), only few studies have
examined the role of endostatin and angiostatin in heart failure (41, 48). We
previously reported that MMP-9 induces endostatin and angiostatin production,
which contribute to transition towards the decompensatory phase of heart failure
(41). Studies in MMP-9 knockout mice have shown attenuation of ventricular
enlargement, collagen deposition, and facilitation of angiogenesis following
experimental myocardial infarction (144-145, 159). There is evidence that TIMP-3
plays an important role in inducing apoptosis as well as inhibiting angiogenesis
(41, 58, 133) . The purpose of this study was to determine whether H2 S could
mitigate the transition from compensatory cardiac hypertrophy to heart failure.
We hypothesize that H2S induces MMP-2 expression and inhibits MMP-9!TIMP-3
expression, thereby promoting angiogenesis which mitigates the transition from
compensatory cardiac hypertrophy to heart failure.
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MATERIAL AND METHODS
Animals

Wild type mice (WT, C57BL6/J) aged 8 weeks were obtained from
Jackson Laboratories (Bar Harbor, Me.; USA) and housed in the animal care
facility at University of Louisville with access to standard chow and water. At the
age of 12 weeks with an approximate weight of 23-25 grams, animals underwent
pressure overload aortic banding (AB) surgery and divided into 2 groups: one
group received 30 Ilmol/liter of sodium hydrogen sulfide (NaHS) in the drinking
water and other received plain water (untreated control). Each group was further
subdivided into sham, 3 weeks after AB surgery (AB 3 weeks group) and 8
weeks after AB surgery (AB 8 weeks group) with respect to the time points they
attain hypertrophy and heart failure. 6 animals per group was used (n=6). After
the study period, animals were euthanized in accordance with National Institute
of Health Guidelines for animal research. The protocol was reviewed and
approved by the Institutional Animal Care and Use Committee (IACUC) of the
University of Louisville.
Pressure overload animal model

Animals were anesthetized with sodium pentobarbital, intubated and
ventilated with Harvard mini ventilator. Body temperature was maintained with a
heating pad (TR 200, Fine Science Tools, Foster City, CA). Under sterile
conditions the thorax was opened by left parasternal thoracotomy, and the
ascending aorta was dissected and separated from adjacent structures. Care
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was taken to maintain proper hemostasis. Aortic banding was performed by
placing a 26 g needle on the aorta and ligating around the vessel with 6-0 silk.
The needle was quickly removed to keep the constricted aorta patent. The
induced pressure overload effectively produced LV hypertrophy within 3 weeks
after AB. The wound was closed in layers using 6-0 vicryl for subcutaneous
tissues and 5-0 silk for the skin (130). All animals received intraperitoneal
injection of Ketofen, 5 mg/Kg body weight for post operative analgesia. Animals
in the sham subgroups underwent similar procedures except aortic banding.
Hydrogen sulfide treatment

Animals were given 6 weeks of H2S in the drinking water in the form of
NaHS (Sigma), which in aqueous solution releases H2S. A 30 Ilmoi/liter
concentration was supplemented to keep the hydrogen sulfide in physiological
range (10-100 Ilmol/l). The diffusion of H2 S into room air is minimal since its
density is 18% higher than that of air. Furthermore the drinking water was
changed daily with fresh NaHS solution to provide adequate levels of H2S to the
mice (160).
Antibodies and Reagents

The following primary antibodies were used for studies: rabbit polyclonal
anti-angiostatin, mouse monoclonal anti-endostatin, rabbit polyclonal MMP-2,
and rabbit polyclonal MMP-9, rabbit polyclonal antibody against TIMP-3; (Abcam,
Cambridge, MA); anti-mouse VEGF antibody ( R&D systems, Minneapolis, MN)
and mouse monoclonal anti-GAPDH (Sigma-Aldrich, St. Louis, MO).
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Following fluorescent secondary antibodies for Immunohistochemistry
(IHC) were ordered from Invitrogen (Carlsbad, CA), Texas Red raised in mouse
and Alexa Fluor 488 and 594 raised in rabbit.
Western blot analysis

Heart tissue from experimental animals and control animals was
harvested and washed thoroughly in PBS and snap-frozen in liquid nitrogen.
Protein extraction was done using 1X RIPA buffer (Tris-HCI 50 mM, pH7.4; NP40 1%; Na-deoxycholate 0.25%; NaCI 150 mM; EOTA 1 mM; PMSF 1 mM;
Na3V04 1 mM; NaF 1 mM; protease inhibitor cocktail 1 I1g/ml). Estimation of
protein was done by BCA method (Thermo fisher, Pittsburgh, PA). 50-75 I1g of
protein was fractionated by SOS-PAGE and transferred onto PVOF membrane
(BioRad, Hercules, CA) by wet transfer method. The transferred proteins were
processed for immunodetection of specific antigens. Briefly, non-specific sites
were blocked with 5% nonfat dry milk in TBS-T (50mM Tris-HCI, 150mM NaCI,
0.1% Tween- 20, pH 7.4) for 1h at room temperature. The blot was then
incubated with appropriate primary antibody in blocking solution according to the
supplier's specific instructions. The blots were washed with TBS-T (3 times, 10
min each) and incubated with appropriate HRP- conjugated secondary antibody
for 1h at room temperature. After washing, ECl Plus substrate (Amersham
Biosciences, Pittsburgh, PA) was applied to the blot for 1min. The blot was
developed using BIO-RAO Chemi Doc XRS + (BIO-RAO laboratories, Hercules,
CA). The blots were stripped and re-probed with GAPOH. The immuno reactive
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bands were scanned and densitometry analyzed by Un-Scan-It software (Silk
Scientific, Orem, UT).
Echocardiography

Transthoracic echocardiography was performed on mice to achieve two
dimensional left ventricle images from an apical view using a SONOS 1500 or
2500; Hewlett-Packard, Inc. and a 12.5 MHz transducer. The procedure was
performed as previously published (41) using tribromo ethanol (TBE) anesthesia
to minimize the cardio depressing actions produced by other anesthetics (135).
First mice were anesthetized with intraperitoneal injection of TBE,(240 mg/kg
body weight dose), depilated with hair removal cream (Nair) and placed on a
heating pad to maintain body temperature. The functional status of the heart was
assessed by LVIDd, LVIDs, LVPWD and %FS. In murine echocardiography %FS
is the most common method to evaluate left ventricular function (161).
Cryosectioning

After mice were euthanized, hearts were harvested and thoroughly
washed in PBS and preserved in Peel-A-Way disposable plastic tissue
embedding moulds (Polysciences inc., Warrington, PA.,USA) filled with tissue
freezing media (Triangle Biomedical Sciences, Durham, N.C., USA) and stored
at 070 0 C until analysis. Tissue sections 5 11m in thickness were made using
Leica CM 1850 Cryocut (Bannockburn, IL, USA). Sections were placed on Super
frost

plus

glass

slides,

air-dried

and

Immunohistochemistry (IHC) staining.
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processed

for

histological

and

Immunohistochemistry

Immunohistochemistry was performed on 5 11m thick frozen tissue
sections using a standard IHC protocol (Abcam). Primary antibodies applied
overnight and included anti-endostatin, anti-TIMP-3 (Abcam) and VEGF antibody
(R&D). A secondary antibody labeled with Texas Red (Invitrogen) was applied for
immunodetection of these proteins. Similarly, primary antibodies anti-MMP-2 and
anti-MMP-9 (Abcam) were applied overnight and secondarily conjugated with
Alexa fluor 488 (Invitrogen) to detect expression of these MMPs. Stained slides
protocol slides were analyzed for fluorescence using a laser scanning confocal
microscope (Olympus FluoView1000) set at the appropriate filter settings.
Masson's Trichrome Staining

Collagen expression in tissue sections was assessed by Masson's
trichrome staining according to the manufacturer's instructions (Richard-Allan
Scientific, Kalamazoo, MI., USA). Collagen identified as blue staining.
Image Proplus software

Images from Immunohistochemistry and Masson's trichrome staining were
analyzed with Image Proplus software.
Pressure volume loop study (P-V loop)

To assess the left ventricular function, pressure-volume study was done
using Millar Pressure-Volume system (Millar Instruments Inc, Houston,TX).
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Following standard Millar protocol, steady state P-V loops were recorded
followed by saline bolus and cuvette calibration for the conversion of RVU
(relative volume units) to ilL. Hemodynamic variables obtained were analyzed by
pressure volume analysis (PVAN) software. The results were used to
substantiate echocardiography findings. % ejection fraction (%EF) was used to
assess the functional status of the left ventricle.
Statistical analysis

All data are expressed as mean ± SE. Data were analyzed using a oneway analysis of variance (ANOVA) to test for treatment effects, and differences
between groups were determined using Tukey's post-hoc test. A p value <0.05
was considered to be significant.

88

-------------------------------------------------------

RESULTS

To determine the effects of H2S on minimizing the remodeling of heart in a
pressure overload mouse model, LV function was evaluated. Echocardiography
data showed a decreased in left ventricular chamber diameter in H2 S treated AB
3 weeks group and AB 8 weeks group compared to untreated controls. These
findings suggest that dilatation of the heart decreases with H2 S treatment (Figure
35). The %FS and the %EF of the heart, representing ventricular function, were
significantly improved in AB 3 weeks and AB 8 weeks H2S treated groups
compared to untreated controls (Figure 36).
Tissue sections were analyzed for changes in fibrosis content following
AB. Interstitial and perivascular collagen deposition analysis demonstrated an
increase in fibrosis after 8 weeks of AB in comparison to sham controls and
animals 3 weeks post-AB. Collagen deposition was significantly reduced in H2 S
treated animals at 3 and 8 weeks post-AB compared to untreated controls
(Figure 37). These findings suggest that H2S decreases vascular resistance and
reduces the effect of pressure overload on heart.
To assess the effect of H2 S on angiogenesis, VEGF was quantified in
tissue sections by IHC and by Western blot analysis. VEGF expression
significantly increased in H2 S-treated animals at 8 weeks post-AB compared to
untreated controls (Figures 39 and 49).
To assess the effect of H2 S on the transition from compensatory to
decompensatory heart failure, anti-angiogenic factor levels were quantified.
Endostatin and angiostatin levels increased in untreated controls, 8 weeks post
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AB compared to sham and in animals 3 weeks post AB. Increasing levels of
endostatin and angiostatin suggest that post-AB angiogenesis at 8 weeks

.

decreased and led to decompensatory heart failure. H2 S treatment significantly
reduced the expression of endostatin and angiostatin in 8 weeks post-AB
animals, compared with untreated control at 8 weeks. These results suggest the
inhibitory action of H2S on anti-angiogenic factors endostatin and angiostatin
(Figures 41 and 49).
To assess the effect of H2 S

on the MMPrrlMP axis in heart failure,

expression of MMP-2, -9, and TIMP-3 levels were quantified. MMP-2 expression
increased in untreated mice 3 weeks post-AB compared to sham and 8 weeks
post-AB mice. Expression of MMP-9 and TIMP-3 increased in untreated mice 8
weeks post-AB compared to sham and 3 weeks post-AB mice. H2 S treatment
increased the expression of MMP-2 after 8 weeks post-AB compared to
untreated controls of same group (Figures 43 and 50). In contrast, H2 S treatment
decreased the expression of both MMP-9 and TIMP-3 at 8 weeks post-AB
compared to untreated controls at 8 weeks (Figures 45,47 & 50). These findings
suggest the beneficial effect of H2 S

is associated with the inhibiton of anti-

angiogenic factors, controlled by the MMPrrlMP axis.
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Sham

AB 3 weeks

~eks

Control

Figure 35: Changes in left ventricular (LV) function following aortic banding (AB)
and the effects of hydrogen sulfide (H 2S) treatment. Representative M-mode
echocardiography images from sham group, AB 3 weeks and AB 8 weeks group.
The effect of H2 S on LV function is shown in lower panel.

Arrows show the

differences in LV internal diameter between treated and untreated animals
compared to their corresponding controls.
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Figure

36:

The

bar

graphs

represent

%FS

and

%EF

obtained

by

echocardiography and pressure-volume loop study. Each bar represents mean ±
SE, n=6 per group. *p <0.05, considered as siginificant.

92

Sham

AB 8 wks

AB 3 wks

Control

Figure 37: Masson's trichrome blue staining of collagen depicting intracardiac

and perivascular fibrosis . Top panel represents heart sections from untreated
sham , 3 weeks post-AS (AS 3 wks) and 8 weeks post-AS (AS 8 wks) groups.
Sottom panel shows the corresponding groups treated with hydrogen sulfide
(H 2 S).
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Figure 38: Quantification of collagen (blue staining) was done with the help of

Image proplus software and represented in bar diagram. Data represents mean ±
SE from n=6 per group; *p<O.05 considered as significant.
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Sham

AB 3 wks

AB 8 wks

Control

Figure 39: Immunohistochemical (IHe) staining of heart sections with vascular

endothelial growth factor (VEGF) , secondarily stained with alexaflour 594 in
sham , 3 weeks post-AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top
panel and corresponding H2 S treated groups in the bottom panel. The expression
of VEGF is seen as red fluorescence intensity.
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Figure 40: Quantification of VEGF stained heart sections in sham, 3 weeks after

aortic banding (AS 3 wks) , and 8 weeks after aortic banding (AS 8 wks) in
untreated controls and their corresponding hydrogen sulfide (H2S) treated
groups.

Data represents mean ±SE from n=6 per group; *p<O.05 was

considered significant.
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Sham

AB 3 wks

AB 8 wks

Control

Figure 41: Immunohistochemical (IHe) staining of heart sections with endostatin ,

secondarily stained with texas red fluorescent antibody in sham , 3 weeks postAS (AS 3 wks) and 8 weeks post-AS (AS 8 wks) in the top panel and
corresponding H2 S treated groups in the bottom panel. The expression of
endostatin is seen as red fluorescence intensity.
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Figure 42: Quantification of endostatin stained heart sections in sham , 3 weeks

after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in
untreated controls and their corresponding hydrogen sulfide (H2S) treated
groups.

Data represents mean ±SE from n=6 per group; *p<O.05 was

considered significant.
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Sham

AB 8 wks

AB 3 wks

Control

Figure 43: Immunohistochemical (IHe) staining of heart sections with MMP-2
antibody, secondarily stained with alexaflour 488 fluorescent antibody in sham, 3
weeks post-AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top panel and
corresponding H2S treated groups in the bottom panel. The expression of MMP-2
is seen as green fluorescence intensity.
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Figure 44: Quantification of MMP-2 stained heart sections in sham, 3 weeks

after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in
untreated controls and the ir corresponding hydrogen sulfide (H2S) treated
groups.

Data represents mean ±SE from n=6 per group; *p<O.05 was

considered significant.
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Sham

AB 8 wks

AB 3 wks

Control

Figure 45: Immunohistochemical (IHe) staining of heart sections with MMP-9
antibody, secondarily stained with alexaflour 488 fluorescent antibody in sham, 3
weeks post-AB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top panel and
corresponding H2S treated groups in the bottom panel. The expression of MMP-9
is seen as green fluorescence intensity.
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Figure 46: Quantification of MMP-9 stained heart sections in sham , 3 weeks
after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in
untreated controls and their corresponding hydrogen sulfide (H2S) treated
groups.

Data represents mean ±SE from n=6 per group; *p<O.05 was

considered significant.
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Sham

AB 8 wks

AB 3 wks

Control

Figure 47: Immunohistochemical (IHe) staining of heart sections with TIMP-3,
secondarily stained with texas red fluorescent antibody in sham, 3 weeks postAB (AB 3 wks) and 8 weeks post-AB (AB 8 wks) in the top panel and
corresponding H2 S treated groups in the bottom panel. The expression of TIMP-3
is seen as red fluorescence intensity.
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Figure 48: Quantification of TIMP-3 stained heart sections in sham , 3 weeks

after aortic banding (AB 3 wks) , and 8 weeks after aortic banding (AB 8 wks) in
untreated controls and their corresponding hydrogen sulfide (H2S) treated
groups.

Data represents mean ±SE from n=6 per group; *p<O.05 was

considered significant.
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Figure 49: Western blot analysis of VEGF-A, angiostatin and endostatin

expression in sham , 3 weeks after aortic banding (AB 3 wks) and 8 wks after
aortic banding (AB 8 wks) in untreated control (first 3 lanes) and their
corresponding hydrogen sulfide (H2S) treated groups (last 3 lanes).Densitometry
analysis of the protein expression in arbitrary units was depicted in bar diagram.
Each bar represents mean ± SE from n= 6 per group and *p <0.05 compared
with untreated sham , #p<0.05 compared to their corresponding untreated
controls.
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Figure 50: Western blot analysis of matrix metalioproteinases-2 &-9 (MMP-2,-9)

and tissue inhibitor of matrix metalioproteinase-3 (TIMP-3) in sham, 3 weeks
after aortic banding (AB 3 wks) and 8 wks after aortic banding (AB 8 wks) in
untreated control (first 3 lanes) and their corresponding hydrogen sulfide (H2S)
treated groups (last 3 lanes). Densitometry analysis of protein expression in
arbitrary units was depicted in bar diagram. Each bar represents mean ± SE from
n=6 per group.*p <0.05 compared with untreated sham, #p<0.05 compared to
their corresponding untreated controls.
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Discussion

Previously we have reported that during compensatory hypertrophy, there
was increase in the expression of MMP-2, which promotes the production of
VEGF. Subsequently, we have shown that in decompensatory phase, MMP-9
expression supersedes MMP-2 expression and induces the production of anti
angiogenic factors, endostatin and angiostatin. This causes the release of TIMP3, resulting in decreased angiogenesis and progression to heart failure.
In the present study, we show that H2S promotes angiogenesis by
inducing MMP-2 production and by inhibiting anti-angiogenic factors endostatin
and angiostatin. H2S also decreases the level of MMP-9 and TIMP-3, thereby
arresting the conversion from compensatory cardiac hypertrophy to heart failure
(Figure 19). Our results showed that the treatment of pressure overload mice
with H2S increases the production of angiogenic factors like VEGF. This
promotes the increase in angiogenesis, and thereby, normalizes the capillary
density and myocyte imbalance. Similarly, MMP-2 expression also increased in
the H2 S treated groups, especially in AS 8 weeks group, supporting the
hypothesis that MMP-2 as an angiogenic promoter, induced VEGF production.
Interestingly, we observed that MMP-9 expression decreased in the H2 S treated
groups along with the expression of anti angiogenic factors like angiostatin,
endostatin and TIMP-3. Since we previously reported that MMP-9 promotes antiangiogenic factor production and TIMP-3 instigates apoptosis, these results
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the role of hydrogen sulfide in inhibiting both anti-angiogenic factor

production and apoptosis by regulating the MMPfTlMP axis.
Previous studies show that TIMP-3 has strong anti-angiogenic activity that
can be seen in all stages of angiogenesis (57). MMP-9 is shown to be induced in
heart failure and generates anti-angiogenic factors, endostatin and angiostatin
(41, 47-48). Researchers report that the MMP-2 expression and activity is
significantly elevated

in

VEGF treated

hypertrophied

hearts

(42).

This

unequivocally suggests that MMP-9 is an anti-angiogenic and MMP-2 is a proangiogenic factor. The treatment with H2S promotes angiogenesis and thereby,
inhibits the transition from compensatory cardiac hypertrophy to heart failure.
Functional data from echocardiography and pressure-volume study also showed
improvement in left ventricular function after treating with H2S in comparison to
untreated control groups.
Clinically, it is well known that heart disease is the leading cause of
mortality not only in the United States but also in rest of the world. Hypertension
is one of the main risk factors leading to heart disease. Our research provides an
insight into the transition mechanism from compensatory cardiac hypertrophy to
heart failure. The beneficial effects of H2S in impeding the transition will help in
clinical outcomes of heart failure.
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Conclusions

Based on our results, we conclude that H2S plays a role in a) ameliorating
left

ventricular

dysfunction

following

pressure

overload,

b)

minimizing

accumulation of collagen deposition in the perivascular and intracardiac
parenchymal tissue, c) altering expression of MMPs and TIMPs and thus
regulating ECM remodeling, d) promoting angiogenesis by stimulating the
production of VEGF, e) inhibiting anti-angiogenic factors like endostatin and
angiostatin.
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CHAPTER VI
SUMMARY AND CONCLUSION

Heart failure is the number one cause of mortality in both men and women
and is a major public health problem around the world. Heart failure is defined as
a pathophysiological state in which an abnormality of cardiac function is
responsible for the failure of the heart to pump blood at a rate commensurate
with the requirements of the metabolizing tissues. The most important risk factors
leading to heart failure are hypertension, myocardial ischemia, myocardial
infarction, valvular disease, and diabetes.
During hypertension, the increase in pressure overload on the heart
produces

a

compensatory

hypertrophy

which

slowly

progresses

to

decompensatory heart failure. The relationship between capillary density and the
size of myofiber is important in heart failure, as the fiber diameter increases the
number of capillaries per square mm decreases (15). The data suggest that as
the myocyte to capillary ratio increases during compensatory hypertrophy, it
eventually will progress to terminal heart failure. The discovery of the
involvement of MMPs and their natural inhibitors TIMPs, in the cardiac
remodeling revolutionized the field of cardiac failure research. Investigators
demonstrate that the alterations in the normal MMPITIMP balance induce cardiac
110

~~-~---------------------------------

matrix remodeling, which plays an important role in the pathogenesis of
hypertension-induced

heart

failure.

Disruption

of

coordinated

cardiac

hypertrophy and angiogenesis leads to heart failure, suggesting the role of
angiogenesis in the pathogenesis of heart failure. Promoting angiogenesis in
severely hypertrophied hearts protects them from ischemic injury. Although the
role of hypertension in the pathogenesis of heart failure is well established, the
treatment of hypertension induced heart failure is unclear. The relatively recent
discovery of H2S, as an endogenous gaseous transmitter has prompted
investigators to use H2S as a therapeutic agent. Studies report that H2S is cardio
protective in hypertension, ischemialreperfusion injury, and infarction, but its
potential role as a therapeutic agent during transition from compensatory cardiac
hypertrophy to heart failure has not been elucidated.
In the present study, we propose that cardiac matrix remodeling during
pressure overload is induced by an increase in angiogenic factors during
compensatory cardiac hypertrophy. Sustained pressure overload causes an
increase in anti-angiogenic factors that leads to decompensatory heart failure.
We also hypothesize that H2S treatment mitigates the transition from
compensatory hypertrophy to decompensatory heart failure.
In the first set of experiments, we found that the pressure overload due to
aortic banding increases expression of pro-angiogenic MMP-2, which in turn
induces production of VEGF during compensatory cardiac hypertrophy.
Overtime, chronic pressure overload induces an increase in expression of MMP111

9 and TIMP-3, which induce collagen deposition and release of anti-angiogenic
factors

like

endostatin

and

angiostatin,

contributing to

a decrease

in

angiogenesis and thus leading to decompensatory heart failure.
In the second set of experiments, we showed that H2S treatment promotes
angiogenesis through increased expression of MMP-2 and VEGF. H2S also
inhibits the production of anti-angiogenic factors by blocking MMP-9fTIMP-3
expression thus mitigating the transition from compensatory cardiac hypertrophy
to heart failure. Therefore, H2 S therapy may become a useful therapeutic agent,
if applied during the compensatory phase of the hypertensive heart failure.
Additional studies are needed to explore further mechanistic details to
understand the pathological mechanism of transition from compensatory
hypertrophy to heart failure.
FUTURE STUDIES

To further elucidate the mechanisms of heart failure due to pressure
overload, it would be interesting to use transgenic mice models of MMP-2-1-,
TIMP-3-1- and MMP-9-1- mice and study the effects of aortic banding in these
animals. Results from these studies will provide confirmatory evidence of the proangiogenic role of MMP-2 and anti-angiogenic role of MMP-9fTIMP-3. Also
studies that selectively inhibit angiostatin and endostatin formation may promote
angiogenesis and may reverse the decompensatory phase of heart failure.
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LIST OF ABBREVIATIONS

Aortic banding (A B)
American Heart Association (AHA)
Protein kinase B (AKT)
Adenosine tri phosphate (ATP)
Carbon monoxide (CO)
Coronary artery disease (CAD)
Cardiovascular disease (CVO)
Congestive heart failure (CHF)
Cluster of differentiation molecule 31 (C031)
Cyclic guanosine mono phosphate (cGMP)
Cystathionine

~

synthase (CBS)

Cystathionine V lyase (CSE)
Endothelial cells (ECs)
Ejection fraction (EF)
Extracellular signal regulated kinase (ERK)
Extracellular matrix (ECM)
Fibroblast growth factor (FGF)
Focal adhesion kinase (FAK)
Fractional shortening (FS)
Guanosine triphosphate (GTP)
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Heam oxygenase (HO)
Hypoxia- inducible factor (HIF)
Hydrogen sulfide (H2S)
Institute Animal Care and use Committee (IACUC)
Integrin

(av~3)

Left ventricular internal dimension in diastole (LVIDd)
Left ventricular posterior wall dimension (LVPWD)
Matrix metalloproteinase (MMP)
Membrane-type matrix metalloproteinase (MT-MMP)
Mitogen-activated protein kinase (MAPK)
National center for health statistics (NCHS)
National Health and Nutrition Examination Survey (NHANES)
Nitric oxide (NO)
Nitric oxide synthase (NOS)
Phosphoglycerate kinase (PGK)
Phosphate buffered saline (PBS)
Platelet endothelial cell adhesion molecule (PECAM)
Pressure volume analysis (PVAN)
Sodium hydrosulfide (NaHS)
Tissue plasminogen activator (tPA)
Tissue inhibitor of matrix metalloproteinase (TIMP)
Tri-bromo ethanol (TBE)
Urikinase plasminogen activator (uPA)
Vascular endothelial growth factor (VEGF)
Vascular endothelial growth factor receptor (VEGFR)
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